We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 856

Life Sciences: Compliance and enforcement in China
  • Ropes & Gray LLP
  • China, Global
  • July 31 2018

A structured guide to compliance and dishonest practices in China


Life Sciences: product regulation and liability in China
  • Ropes & Gray LLP
  • China, Global
  • July 31 2018

A structured guide to product regulation and liability laws in China


Clinical trials in China
  • Ropes & Gray LLP
  • China, Global
  • July 31 2018

A structured guide to clinical trials in China


Enforcement and Litigation Strategies: Skadden’s Eighth Annual Pharmaceutical, Biotechnology and Medical Device Seminar
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • March 29 2018

On March 15, 2018, Skadden hosted its Eighth Annual Pharmaceutical, Biotechnology and Medical Device Seminar in Palo Alto, California, which focused


Which Patent Trial and Appeal Board Trial Decisions Cannot be Appealed?
  • Banner & Witcoff Ltd
  • USA
  • March 26 2018

The U.S. Court of Appeals for the Federal Circuit heard oral arguments on March 6, 2018, in the appeal of Altaire Pharmaceuticals, Inc. v. Paragon


Procedures and strategies for pharmaceutical brands: United States
  • Baker McKenzie
  • USA
  • March 13 2018

Clearing and registering pharmaceutical trademarks in the United States are often more complex and challenging than in other countries. This is due in


Efforts to Cut Drug Prices in Medicaid
  • Manatt Phelps & Phillips LLP
  • USA
  • February 27 2018

Over the past five years, the budgets of state Medicaid programs have been challenged by the introduction of new high-cost drugs into the marketplace


FDA Guidance on Regulatory Classification of Pharmaceutical Co-Crystals
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • February 20 2018

On February 14, 2018, FDA released a final guidance titled “Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry.” The


The Internet of Pills: The FDA’s Approval of Digital Smart Pills Takes the Internet of Things to New Levels
  • Gordon Rees Scully Mansukhani
  • USA
  • November 15 2017

If your insurance company knew that you did not take your medication as prescribed, could it deny future coverage? Could your physician refuse to


FTC Holds Public Workshop to Consider If Hatch-Waxman Is Working for Prescription Drug Competition
  • Arent Fox LLP
  • USA
  • November 13 2017

On November 8, 2017, the Federal Trade Commission held a workshop entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply